|Articles|September 1, 2018
- Pharmaceutical Executive-09-01-2018
- Volume 38
- Issue 9
Pharmaceutical Executive, September 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Executive September 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 7 years ago
Paul Perreault: The Global CEOabout 7 years ago
Specialty Pharma’s Move to Mainstreamabout 7 years ago
Specialty Product Launch Insightsabout 7 years ago
Beyond Big Data: Meeting the Specialty Marketing Challengeabout 7 years ago
Specialty Focus: Tackling Rare Mutation in CFabout 7 years ago
The ‘Spare-No-Expense’ Alternativeabout 7 years ago
Pharm Exec's 17th Annual Industry Auditabout 7 years ago
Specialty Supply Chain Decisionsabout 7 years ago
FDA Struggles to Advance Biosimilarsabout 7 years ago
Country Report: UKNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Merck Planning $70 Billion Investment for US Expansion
2
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
